Hunt NB, Pajouheshnia R, Salih A, van Doorn S, Souverein PC, Bazelier MT, Klungel OH, Gardarsdottir H. Prescribing of low-dose rivaroxaban in patients with atherosclerotic cardiovascular disease in the United Kingdom and the Netherlands. Br J Clin Pharmacol. 2023 Jul;89(7):2263-71. doi: 10.1111/bcp.15708
van den Dries CJ, Pajouheshnia R, van den Ham HA, Souverein P, Moons KGM, Hoes AW, Geersing GJ, van Doorn S. Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Br J Clin Pharmacol. 2023 Feb;89(2):751-61. doi: 10.1111/bcp.15534
Leung MW, Bazelier MT, Souverein PC, Uitdehaag BM, Klungel OH, Leufkens HG, Pajouheshnia R. Mapping the risk of infections in patients with multiple sclerosis: a multi-database study in the United Kingdom clinical practice research datalink GOLD and aurum. Mult Scler. 2022 Oct;28(11):1808-18. doi: 10.1177/13524585221094218.
Gemmeke M, Koster ES, Pajouheshnia R, Kruijtbosch M, Taxis k, Bouvy ML. Using pharmacy dispensing data to predict falls in older individuals. Br J Clin Pharmacol. 2021 Mar;87(3):1282-90. doi: 10.1111/bcp.14506
Weatherall M, Aantaa R, Conti G, Garratt CJ, Pohjanjousi P, Lewis MA, Moore N, Perez-Gutthann S. A multinational, drug utilisation study to investigate the use of dexmedetomidine (Dexdor®) in clinical practice in the EU. Br J Clin Pharmacol. 2017 Sep;83(9):2066-76. doi: 10.1111/bcp.13293
Schmiedl S, Fischer R, Ibanez L, Fortuny J, Thurmann P, Ballarin E, Ferrer P, Sabate M, Rottenkolber D, Gerlach R, Tauscher M, Reynolds R, Hasford J, Rottenkolber M. Tiotropium Respimat® vs. HandiHaler®: real-life usage and TIOSPIR trial generalizability. Br J Clin Pharmacol. 2016 Feb;81(2):379-88. doi: 10.1111/bcp.12808
Meads DM, Doward LC, McKenna SP, Fisk J, Twiss J, Eckert B. The development and validation of the Unidimensional Fatigue Impact Scale (U-FIS). Mult Scler. 2009 Oct 1;15(10):1228-38. doi: 10.1177/1352458509106714
Miret M, Perez-Gutthann S, Gutierrez LP, Viglietta V, Musch B, Greenberg S. Evaluation of the long-term safety of Cladribine tablets: design of a prospective 8-year safety registry. Poster presented at the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS); 2009. Dusseldorf, Germany. [abstract] Mult Scler. 2009 Sep 8; 15(Issue Suppl_9):S239. doi: 10.1177/1352458509106963
Doward LC, McKenna SP, Meads DM, Twiss J, Eckert BJ. The development of Patient Reported Outcome Indices for Multiple Sclerosis (PRIMUS). Mult Scler. 2009 Sep 1;15(9):1092-102.
Arana A, Cuchi T, Arellano F. Strengthening EU pharmacovigilance. European pharmaceutical contractor. European pharmaceutical contracto: EPC. 2009;44-5.
Doward LC, McKenna SP, Meads DM, Twiss J, Hagell P, Oprandi N. Psychometric and scaling properties of the patient reported outcome indices for multiple sclerosis (PRIMUS). Mult Scler. 2007 Jun;13(Suppl 2):S219.
Doward LC, Meads DM, Fisk JD, McKenna SP, Eckert BJ. Derivation of a unidimensional scale from the fatigue impact scale. Mult Scler. 2006 Sep;12(Suppl 1):S1-S228.
Garcia Rodriguez LA, Duque A, Castellsague J, Perez-Gutthann S, Stricker BH. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol. 1999 Dec 1;48(6):847-52.
Garcia Rodriguez LA, Perez GS. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol. 1998 May 1;45(5):419-25.